Danaher DHR Biotechnology — Goodwill
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Danaher in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The official record: Danaher’s 10-Q, filed July 21, 2026, on SEC EDGAR. View the filing →
Ask your AI about Danaher's biotechnology — goodwill.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Danaher's biotechnology — goodwill?
- Danaher (DHR) reported biotechnology — goodwill of $22.73B in Q2 2026.
- How has Danaher's biotechnology — goodwill changed year-over-year?
- Danaher's biotechnology — goodwill decreased by 1.8% year-over-year, from $23.14B to $22.73B.
- What is the long-term trend for Danaher's biotechnology — goodwill?
- Over 2 years (2023 to 2025), Danaher's biotechnology — goodwill has grown at a 2.1% compound annual growth rate (CAGR), from $88.21B to $91.91B.
- What does biotechnology — goodwill mean?
- The premium paid over the fair value of net assets during the acquisition of businesses integrated into the biotechnology segment. It represents intangible benefits such as brand reputation, customer loyalty, and synergies. This balance is subject to periodic impairment testing to ensure it remains supported by future cash flows.